Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.
Pfizer (NYSE:PFE | PFE Price Prediction) pays a 6.16% dividend yield. For a drugmaker worth roughly $159.5 billion, a number that large works as a warning label. The question for income investors is fairly simple: is that yield a reward for patience, or is the market saying the payout is in trouble?
Why Pfizer’s Yield Looks So Big
Yield is the annual dividend divided by the share price. Pfizer pays $1.72 per share a year. When the price falls, the same payment becomes a bigger percentage. Five years ago the stock traded at $32.55, which would yield about 5.28% today. Shares now sit at $27.98, down 14.04% over five years, despite an 18.2% gain in 2026.
The peers make the point clearer. Bristol-Myers Squibb (NYSE:BMY), which has its own patent expiration to worry about, yields 4.2%. Merck (NYSE:MRK), whose growth story still has investors’ confidence, yields just 2.33% and trades at 15 times forward earnings. Pfizer trades at 10 times.
Cash Coverage Is Thinner Than Earnings Suggest
Measured against adjusted earnings, the dividend looks comfortable at about 59% of the center of Pfizer’s $2.80 to $3.00 adjusted EPS guidance. Cash flow is tighter. In 2025, operating cash flow of $11.7 billion minus $2.63 billion in capital spending left free cash flow of about $9.08 billion. Dividends cost $9.77 billion, roughly 108% of free cash flow. In the first half of 2026, operating cash flow was $3.45 billion while dividends took $4.9 billion.
The balance sheet carries $63.2 billion of debt, with net debt at 3.26 times EBITDA. Management expects leverage to stay around current level or modestly higher through patent expiration. Pfizer made no buybacks in 2025 and expects none in 2026. The dividend has stayed at $0.43 per quarter since January 2025, confirmed again on October 6, 2026.
Bourla Says the Dividend Will Hold
On the second-quarter call, CEO Albert Bourla took the question head on:
“We feel extremely confident that we will, even the most stretched scenarios that we are running, we will be able to maintain our dividend. So I want once and for all to make that clear to all that the dividend will be maintained and eventually after the LOE period will start again growing it.”
That plan faces significant challenges. Paxlovid revenue was $21 million in the quarter, down 95%, and 2026 COVID revenue outlook fell to about $4 billion. A failed Phase 3 trial cost $3.8 billion in write-downs and caused a GAAP quarterly loss. Making up for this, launched and acquired products grew 18%, cost cuts are expected to save $6.7 billion through 2029, and a patent settlement protects Vyndamax in the U.S. until June 2031.
What Has to Go Right Before 2029
To hold the payout, Pfizer needs cost savings on schedule, newer drugs growing at double digits, and its obesity drug reaching first approval by 2028. Risks include late-stage trial failures, U.S. drug-pricing pressure, or leverage rising well past slightly higher.
Here is the answer. The dividend is safe. Pfizer has the earnings buffer, a CEO who has publicly committed to it, and room to borrow while it waits for growth to return. The 6.16% yield is the market charging for that wait.
Investors collect a frozen payout, partly paid for with debt, until growth returns around 2029. That is slow income with a solid floor. The risk is how long the wait lasts.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
